The antiinfective medicine sales per capita in Canada show a declining trend from 2024 to 2028, with values decreasing from 42.9 USD per capita in 2024 to 41.9 USD per capita in 2028. From 2024 onwards, this steady decline represents a negative pricing model or a decreased demand. Historically, the trend from 2023 showed stability, indicating a stable market but shifting dynamics. The average year-on-year variation shows a slight negative trend that reflects minor annual decreases, perhaps due to market saturation or advanced infection control methods.
- Monitor the impact of innovative medical technologies that might disrupt traditional antiinfective treatment.- Keep an eye on any regulatory changes that might alter market conditions.- Assess potential market shifts towards personalized medicine, impacting traditional volume sales.
